-
47m 54sPart 1 | Session 1 View from the Thoraxcenter: ESC 25 Late-breaking Science Wrap-Up
-
36m 33sPart 1 | Session 2 View from the Thoraxcenter: What's Hot at ESC 25?
-
11m 8sPart 2 | Session 1 Day 4 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
19m 8sPart 2 | Session 2 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
13m 11sPart 2 | Session 3 Day 2 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
14m 10sPart 2 | Session 4 Day 1 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
13m 4sPart 3 | Session 1 VICTOR: Vericiguat in Heart Failure
-
12m 24sPart 3 | Session 2 DIGIT-HF: Cardiac Glycosides in HFrEF
-
12m 36sPart 3 | Session 3 BETAMI-DANBLOCK: Beta-blockers after MI
-
14m 3sPart 3 | Session 4 ESC 25 Guidelines Discussion: Management of Dyslipidaemias
-
14m 30sPart 3 | Session 5 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
-
27m 8s
-
4m 15sPart 4 | Session 1 TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
-
3m 52sPart 4 | Session 2 The VICTOR & VICTORIA Pooled Analysis
-
5m 10s
-
7m 42sPart 4 | Session 4 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism
-
7m 12s
-
6m 54sPart 4 | Session 6 STEEER-AF Cluster Randomised Trial by the ESC and EHRA
-
10m 5sPart 4 | Session 7 NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency
-
7m 43s
-
6m 35sPart 4 | Session 9 SWEDEPAD 1 and 2: Drug-Coated Devices in Peripheral Arterial Disease
-
5m 6sPart 4 | Session 10 Lifetime Benefits of Combination Therapy in HFpEF
-
3m 53sPart 4 | Session 11 REBOOT-CNIC: Beta-blockers After Infarction with LVEF Greater Than 40%
-
4m 31sPart 4 | Session 12 ODYSSEY-HCM: Mavacamten in Non-obstructive Hypertrophic Cardiomyopathy
-
6m 37sPart 4 | Session 13 Pooled MACE Data for Obicetrapib
-
8m 9sPart 4 | Session 14 STRIDE: Outcomes by Sex
-
4m 27sPart 4 | Session 15 The SEMA-VR CardioLink-15 Trial
-
7m 20sPart 4 | Session 16 The CARUSO Trial: Carotid Plaques Stabilisation and Regression with Evolocumab
-
3m 38sPart 4 | Session 17 EMORI-HCM: Electromagnetically Optimised Right Ventricular Pacing for oHCM
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.
Trials covered in detail include:
REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction
BETAMI-DANBLOCK: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure
DIGIT-HF: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction
AQUATIC: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation
Recorded remotely from Los Angeles, 2025.
Editors: Jordan Rance, Yazmin Sadik, Mirjam Boros.
Videographers: David Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
Dive into our coverage of ESC Congress 2025 for groundbreaking trial results and discussions with expert faculty.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- Watch our Wrap-Up series led by Dr Mirvat Alasnag summarising the key take-aways from each day of the congress.
- For clinical trial data from principal investigators, keep up with Dr Harriette Van Spall's Late-Breaker Discussion series.
- Our concise, accessible Expert Interviews will focus on the current data and it's impact on clinical practice.
- Don't miss the Highlights series to stay ahead of the curve in each field.
- In the Journal Discussions series, authors of ECR Journal explore their special focuses in depth.
More from this programme
Part 1
View from the Thoraxcenter: What's Hot at ESC 25?
Part 2
Daily Wrap Ups with Dr Mirvat Alasnag
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Faculty Biographies
Michelle Kittleson
Cardiologist & Professor of Medicine
Dr Michelle Kittleson is Professor of Medicine at Cedars-Sinai and Director of Education in Heart Failure and Transplantation at the Smidt Heart Institute. She graduated from Harvard College and received her medical degree from Yale University. She completed residency training at Brigham and Women's Hospital and cardiology fellowship at Johns Hopkins, where she also received a PhD in Clinical Investigation.
Dr Kittleson is Interim Editor-in-Chief of the Journal of Heart and Lung Transplantation, on writing committees for the ACC/AHA Hypertrophic Cardiomyopathy Guidelines and the ACC/AHA/HFSA HF Guidelines, Co Editor-in-Chief for the ACC Heart Failure Self-Assessment Program, and on the Board of Directors for the Heart Failure Society of America. Her essays have appeared in the New England Journal of Medicine, Annals of Internal Medicine…
Comments